442 related articles for article (PubMed ID: 28018099)
1. Understanding the role of PIN1 in hepatocellular carcinoma.
Cheng CW; Leong KW; Tse E
World J Gastroenterol; 2016 Dec; 22(45):9921-9932. PubMed ID: 28018099
[TBL] [Abstract][Full Text] [Related]
2. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
3. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin.
Cheng CW; Chow AK; Pang R; Fok EW; Kwong YL; Tse E
Am J Pathol; 2013 Mar; 182(3):765-75. PubMed ID: 23333752
[TBL] [Abstract][Full Text] [Related]
4. PIN1 in hepatocellular carcinoma is associated with TP53 gene status.
Bae JS; Noh SJ; Kim KM; Jang KY; Park HS; Chung MJ; Park BH; Moon WS
Oncol Rep; 2016 Oct; 36(4):2405-11. PubMed ID: 27499097
[TBL] [Abstract][Full Text] [Related]
5. Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma.
Cheng CW; Tse E
Front Cell Dev Biol; 2019; 7():369. PubMed ID: 32010690
[TBL] [Abstract][Full Text] [Related]
6. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development.
Pu W; Li J; Zheng Y; Shen X; Fan X; Zhou JK; He J; Deng Y; Liu X; Wang C; Yang S; Chen Q; Liu L; Zhang G; Wei YQ; Peng Y
Hepatology; 2018 Aug; 68(2):547-560. PubMed ID: 29381806
[TBL] [Abstract][Full Text] [Related]
7. Peptidyl-Prolyl cis/trans Isomerase NIMA-Interacting 1 as a Therapeutic Target in Hepatocellular Carcinoma.
Kim G; Kim JY; Choi HS
Biol Pharm Bull; 2015; 38(7):975-9. PubMed ID: 26133706
[TBL] [Abstract][Full Text] [Related]
8. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression.
Leong KW; Cheng CW; Wong CM; Ng IO; Kwong YL; Tse E
Oncotarget; 2017 Feb; 8(7):11343-11355. PubMed ID: 28076852
[TBL] [Abstract][Full Text] [Related]
9. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma.
Pang R; Yuen J; Yuen MF; Lai CL; Lee TK; Man K; Poon RT; Fan ST; Wong CM; Ng IO; Kwong YL; Tse E
Oncogene; 2004 May; 23(23):4182-6. PubMed ID: 15064734
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.
Liao P; Zeng SX; Zhou X; Chen T; Zhou F; Cao B; Jung JH; Del Sal G; Luo S; Lu H
Mol Cell; 2017 Dec; 68(6):1134-1146.e6. PubMed ID: 29225033
[TBL] [Abstract][Full Text] [Related]
11. PIN1 in Cell Cycle Control and Cancer.
Cheng CW; Tse E
Front Pharmacol; 2018; 9():1367. PubMed ID: 30534074
[TBL] [Abstract][Full Text] [Related]
12. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
[TBL] [Abstract][Full Text] [Related]
13. Pin1 impairs microRNA biogenesis by mediating conformation change of XPO5 in hepatocellular carcinoma.
Li J; Pu W; Sun HL; Zhou JK; Fan X; Zheng Y; He J; Liu X; Xia Z; Liu L; Wei YQ; Peng Y
Cell Death Differ; 2018 Sep; 25(9):1612-1624. PubMed ID: 29445125
[TBL] [Abstract][Full Text] [Related]
14. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.
Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP
Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
[TBL] [Abstract][Full Text] [Related]
16. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.
Wulf GM; Ryo A; Wulf GG; Lee SW; Niu T; Petkova V; Lu KP
EMBO J; 2001 Jul; 20(13):3459-72. PubMed ID: 11432833
[TBL] [Abstract][Full Text] [Related]
17. Rhein exhibits antitumorigenic effects by interfering with the interaction between prolyl isomerase Pin1 and c-Jun.
Cho JH; Chae JI; Shim JH
Oncol Rep; 2017 Mar; 37(3):1865-1872. PubMed ID: 28184937
[TBL] [Abstract][Full Text] [Related]
18. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer.
Ryo A; Liou YC; Lu KP; Wulf G
J Cell Sci; 2003 Mar; 116(Pt 5):773-83. PubMed ID: 12571275
[TBL] [Abstract][Full Text] [Related]
19. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells.
Ryo A; Liou YC; Wulf G; Nakamura M; Lee SW; Lu KP
Mol Cell Biol; 2002 Aug; 22(15):5281-95. PubMed ID: 12101225
[TBL] [Abstract][Full Text] [Related]
20. Dual Roles of Pin1 in Cancer Development and Progression.
Han HJ; Choi BY; Surh YJ
Curr Pharm Des; 2017 Nov; 23(29):4422-4425. PubMed ID: 28671058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
